daraxonrasib Updated Jul 2
Daraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.
- Phase 3 RASolute 302 results were striking: median OS 13.2 vs 6.7 months (HR 0.40), roughly doubling survival in one of the hardest-to-treat cancers (source: Dana-Farber / ASCO 2026, cancertherapyadvisor.com).
- Pan-RAS coverage is a key differentiator, daraxonrasib inhibits multiple RAS mutations (G12X, G13X, Q61X) and wild-type RAS, unlike approved KRAS G12C-only drugs from Amgen and BMS, giving it a much larger addressable patient population (source: eureka.patsnap.com competitive analysis).
- FDA has granted Breakthrough Therapy Designation, Orphan Drug Designation, and a Commissioner's National Priority Voucher, all signals of accelerated regulatory review and government prioritization (source: ir.revmed.com press release, June 2025).
- The defining binary catalyst, the Phase 3 topline readout, has already passed (April 13, 2026). The stock surged ~258% in 12 months and trades near its 52-week high of ~$193, suggesting much of the good news is already priced in.
- No confirmed PDUFA date yet. The company stated intent to submit an NDA under the CNPV program, but there is no guarantee of acceptance, priority review, or approval timeline (source: fda.gov press release, May 1, 2026).
- Insider selling: CEO Mark Goldsmith filed Form 144 to sell ~$1.5M of stock in June 2026. Director Sushil Patel exercised options and sold shares in the $182-$193 range under a 10b5-1 plan.